Uptal Patel is Chief Medical Officer at HI-Bio. Prior to HI-Bio, he was the Head of Clinical Renal and Executive Group Director in Early CVRM at AstraZeneca where he led early clinical strategy and development for a wide range of therapies that address several kidney diseases. He previously led the kidney diseases domain at Gilead Sciences. He currently also serves as Chair of the Board of Directors for the Kidney Health Initiative.

As a faculty member at Duke University, he led clinical and translational research programs to improve detection and management of kidney disease in populations. He completed training at the University of Michigan in internal medicine, pediatrics, adult nephrology, pediatric nephrology, and health services research as a Robert Wood Johnson Clinical Scholar after attending medical school at UCSF.